Amatuximab
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN) . Mesothelin is a glycosylphosphatidyl inositol (GPI) -anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium[1][2].
Product Specifications
CAS Number
931402-35-6
Product Name Alternative
MORab-009
UNSPSC
12352203
Target
Mesothelin
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/amatuximab.html
Purity
99.90
Solubility
H2O
Smiles
[Amatuximab]
Molecular Weight
(144.363 kDa)
References & Citations
[1]Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20 (23) :5927-5936. |[2]Baldo P, et al. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337-5353. Published 2017 Nov 8.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
